Cholangiocarcinoma Market revenue to hit USD 1.3 Billion by 2036, says Research Nester [Yahoo! Finance]
Agios Pharmaceuticals, Inc. (AGIO)
Last agios pharmaceuticals, inc. earnings: 4/30 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.agios.com/investor-overview
Company Research
Source: Yahoo! Finance
Corporation, Agios Pharmaceuticals, Specialised Therapeutics, PlantPraxis Biotecnologia, and Dr. Reddy Laboratories. New York , Dec. 07, 2023 (GLOBE NEWSWIRE) -- The global cholangiocarcinoma market size is projected to grow at a CAGR of over 4% from 2024 to 2036. The market is expected to garner a revenue of USD 1.3 billion by the end of 2036, up from a revenue of USD 800 million in the year 2023. The growth of the market is due to growing infections like liver fluke which will drive market demand. In more than 70 nations across the world, at least 2.4 million individuals are infected and several million more are at danger, particularly in areas where sheep or cattle are raised. Also, increasingly, combination therapy and the necessity for medications with low side effects are some of the factors projected to propel market expansion. Request Free Sample Copy of this Report @ https://www.researchnester.com/sample-request-5383 In addition to these, in an effort to enhance the sta
Show less
Read more
Impact Snapshot
Event Time:
AGIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AGIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AGIO alerts
High impacting Agios Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AGIO
News
- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $55.00 price target on the stock.MarketBeat
- Agios Pharmaceuticals (AGIO) Appreciated after Positive Testing Results [Yahoo! Finance]Yahoo! Finance
- Companies Like Agios Pharmaceuticals (NASDAQ:AGIO) Are In A Position To Invest In Growth [Yahoo! Finance]Yahoo! Finance
- Agios Pharmaceuticals' tebapivat gains FDA orphan drug designation [Yahoo! Finance]Yahoo! Finance
AGIO
Earnings
- 8/1/24 - Miss
AGIO
Sec Filings
- 8/13/24 - Form 4
- 8/13/24 - Form 4
- 8/12/24 - Form 4
- AGIO's page on the SEC website